Use of novel insertion sites for the development of polyvalent ORFV D1701-V vectored vaccines

DSpace Repository


Dateien:

URI: http://hdl.handle.net/10900/96585
http://nbn-resolving.de/urn:nbn:de:bsz:21-dspace-965859
http://dx.doi.org/10.15496/publikation-37968
Dokumentart: Dissertation
Date: 2021-12-11
Language: English
Faculty: 7 Mathematisch-Naturwissenschaftliche Fakultät
Department: Biologie
Advisor: Rammensee, Hans-Georg (Prof. Dr.)
Day of Oral Examination: 2019-12-11
DDC Classifikation: 500 - Natural sciences and mathematics
570 - Life sciences; biology
610 - Medicine and health
Keywords: Impfstoff
License: Publishing license including print on demand
Order a printed copy: Print-on-Demand
Show full item record

Inhaltszusammenfassung:

Dissertation ist gesperrt bis 11. Dezember 2021 !

Abstract:

Viral vector-based vaccines are promising to elicit strong cellular and humoral immune responses. Within the genus Parapoxvirus of the Poxviridae, the Orf Virus (ORFV) strain D1701-V comprises various properties particularly favorable for the development of a vector platform technology and was shown to facilitate various vaccination approaches. To enhance viral vectors’ immunogenicity, current strategies implement the use of immunomodulatory elements and the elimination of viral immunomodulatory genes still present in the viral genome. To allow the insertion of multiple transgenes into a single vector, the present work examines the suitability of novel insertion sites for transgene expression by simultaneous deletion of ORFV D1701-V encoded genes non-essential for viral replication. Novel D1701-V deletion mutants were subjected to detailed characterization of the genetic stability of inserted transgenes, their growth behavior and capability to induce transgene expression in different target cells in vitro. Additionally, the D1701-V mutants’ immunogenicity was analyzed by their ability to activate pro-inflammatory pathways, peripheral blood mononuclear and antigen presenting cells, or to induce antigen-specific immune responses in vitro and in vivo. Additionally, proof-of-concept studies were performed to evaluate the suitability of ORFV D1701-V recombinants for the expression of immune checkpoint inhibitors (ICIs).

This item appears in the following Collection(s)